EP3331571A4 - Compositions and methods to treat viral infections - Google Patents

Compositions and methods to treat viral infections Download PDF

Info

Publication number
EP3331571A4
EP3331571A4 EP16804107.7A EP16804107A EP3331571A4 EP 3331571 A4 EP3331571 A4 EP 3331571A4 EP 16804107 A EP16804107 A EP 16804107A EP 3331571 A4 EP3331571 A4 EP 3331571A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
viral infections
treat viral
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16804107.7A
Other languages
German (de)
French (fr)
Other versions
EP3331571A1 (en
Inventor
Stephen R. Quake
Jianbin Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenovir Corp
Original Assignee
Agenovir Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenovir Corp filed Critical Agenovir Corp
Publication of EP3331571A1 publication Critical patent/EP3331571A1/en
Publication of EP3331571A4 publication Critical patent/EP3331571A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
EP16804107.7A 2015-05-29 2016-05-27 Compositions and methods to treat viral infections Withdrawn EP3331571A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168262P 2015-05-29 2015-05-29
US201562168259P 2015-05-29 2015-05-29
PCT/US2016/034606 WO2016196273A1 (en) 2015-05-29 2016-05-27 Compositions and methods to treat viral infections

Publications (2)

Publication Number Publication Date
EP3331571A1 EP3331571A1 (en) 2018-06-13
EP3331571A4 true EP3331571A4 (en) 2019-04-10

Family

ID=57441664

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16804107.7A Withdrawn EP3331571A4 (en) 2015-05-29 2016-05-27 Compositions and methods to treat viral infections

Country Status (4)

Country Link
EP (1) EP3331571A4 (en)
JP (1) JP2018516983A (en)
CA (1) CA3000189A1 (en)
WO (1) WO2016196273A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
GB2543873A (en) * 2015-05-29 2017-05-03 Agenovir Corp Compositions and methods for cell targeted HPV treatment
EP3365357B1 (en) 2015-10-23 2024-02-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (en) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and Compositions for Evolving Base Editing Factors Using Phage-Supported Continuous Evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
JP2022526908A (en) 2019-03-19 2022-05-27 ザ ブロード インスティテュート，インコーポレーテッド Editing Methods and Compositions for Editing Nucleotide Sequences
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2023540427A (en) * 2020-07-07 2023-09-25 オリエンジーン バイオテクノロジー リミテッド Guide RNA and method for HSV-1 gene editing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150098954A1 (en) * 2013-10-08 2015-04-09 Elwha Llc Compositions and Methods Related to CRISPR Targeting

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016196273A1 *
YANWEI BI ET AL: "High-Efficiency Targeted Editing of Large Viral Genomes by RNA-Guided Nucleases", PLOS PATHOGENS, vol. 10, no. 5, 1 May 2014 (2014-05-01), pages e1004090, XP055198358, DOI: 10.1371/journal.ppat.1004090 *

Also Published As

Publication number Publication date
EP3331571A1 (en) 2018-06-13
CA3000189A1 (en) 2016-12-08
JP2018516983A (en) 2018-06-28
WO2016196273A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
EP3331571A4 (en) Compositions and methods to treat viral infections
EP3397261A4 (en) Methods and compositions relating to chondrisomes
IL251527A0 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
EP3379935A4 (en) Methods and compositions for reducing vancomycin-resistantenterococci
EP3356390A4 (en) Methods and compositions for antibody-evading virus vectors
EP3325620A4 (en) Antiviral methods and compositions
EP3313404A4 (en) Therapeutic compositions, combinations, and methods of use
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
EP3145493A4 (en) Methods and compositions relating to exosomes
EP3256113A4 (en) Treatment of hypoparathyroidism
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
EP3166593A4 (en) Topical antiviral compositions and methods of using the same
EP3157565A4 (en) Treatment of polybacterials infections
EP3307330A4 (en) Method of treatment using oncolytic viruses
EP3512524A4 (en) Method and compositions for treating viral infection
EP3253389A4 (en) Apilimod compositions and methods for using same
HK1252343A1 (en) Compositions and methods for the treatment of viral infection
EP3253211A4 (en) Compositions and methods for treatment of edema
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
EP3250553A4 (en) Compositions and methods for inhibiting viral infection
EP3310382A4 (en) Compositions and methods for modulating viral infection
EP3642415A4 (en) Nanolignocellulose compositions and processes to produce these compositions
EP3250550A4 (en) Compositions and methods for viral sensitization
EP3204426A4 (en) Compositions and methods for treating viral hemorrhagic fever

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20180416

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENOVIR CORPORATION

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190308

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101AFI20190304BHEP

Ipc: A61K 9/08 20060101ALI20190304BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1255580

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191008